HYBRID EVENT: Join us in person in Tokyo, Japan or attend virtually from anywhere.
Emerging therapies for childhood leukemia are offering new hope for improving outcomes in this challenging pediatric cancer. Leukemia is the most common cancer in children, and traditional treatments like chemotherapy and stem cell transplants have proven effective but come with significant risks and side effects. Recent advances in immunotherapy, including CAR T-cell therapy and immune checkpoint inhibitors, have shown promise in targeting leukemia cells more precisely while sparing healthy tissue. Targeted therapies that focus on the specific genetic mutations driving leukemia have also led to breakthroughs in treatment. These new therapies aim to improve survival rates and reduce the long-term health impacts of treatment, making childhood leukemia more manageable and treatable.
